GenWorks Launches In-Vitro Diagnostic Tests to Curb Monsoon Epidemics of Dengue and Malaria

New Delhi (India), June 29: The medical industry has grown leaps and bounds in terms of diagnosis and prevention of diseases particularly after the pandemic. IVD is significant in preventing, diagnosing, and treating ailments for relieving the stress on the healthcare industry and improving the quality of life of the affected people. As the healthcare industry in India witnesses a transformation with each passing day, there is also rising customer awareness about the importance of investing in healthcare and government policies that drive this change. This is a factor that can be validated by ensuring easy access to affordable diagnostics across the last mile of India. The IVD Vertical of GenWorks Health works in alignment with the core of enabling affordable healthcare access for patients.

GenWorks Health has been consistently working to contribute timely diagnostic solutions at a cost-effective price. With a wide-ranging portfolio in Chemistry, Haematology, Urinalysis, Immunoassay and Point-of-Care tests, GenWorks has enabled early diagnosis of many diseases leading to effective treatment. To improve the offering in the IVD field, GenWorks has come up with Rapid Card test kits for Dengue and Malaria.

With the onset of monsoon season, the Indian population again gears up to protect itself from the diagnosis and treatment of diseases such as Dengue and Malaria. Co-infection poses a big challenge for the precise diagnosis of these viral diseases as misdiagnosis due to false positive results leads to negative outcomes and fatal consequences at times. The In-Vitro Diagnostic products for Dengue and Malaria are for curing seasonal epidemics and mitigating their impact. Their use is aimed at preventing, diagnosing, and treating ailments for relieving the stress on the healthcare industry and improving the quality of life in those affected.

Malaria infection in human beings is caused by four species of Plasmodium parasites namely P. falciparum, P. vivax, P. ovale and P. malariae. Out of these four species, P. falciparum and P. Vivax infections are the most common, at times fatal. Early detection and differentiation of malaria infection are very vital for the timely management of the patient. iScreen Malaria Card Antigen (Pf/Pv) by GenWorks is a visual lateral flow immunoassay designed for the qualitative and differential detection of P. falciparum specific histidine-rich protein-2 (Pf. HRP-2) and P. Vivax specific lactate dehydrogenase (pLDH) in human whole blood with 98.5% sensitivity & 95% specificity. A blood specimen collected from the patient is applied to the sample pad on the test card along with buffer reagent. After 15 minutes, the presence of specific bands in the test card window indicates whether the patient is infected with Plasmodium falciparum or Plasmodium vivax of human malaria.

On the other hand, Dengue virus belongs to the Flavivirus group of viruses transmitted by Aedes aegypti and Aedes albopictus mosquitoes, widely distributed throughout the tropical and subtropical areas of the world. Dengue fever is very common in the rainy season. Primary Dengue infection is associated with mild to high fever, headache, muscle pain and skin rashes. NS1 antigen is found from the first day and up to 9 days after the onset of fever in samples of primary or secondary dengue-infected patients. IgM antibodies are produced by the 5th day of symptoms and persist for 30-60 Days. In primary infections, IgG appears on the 14th day and persists for life. Secondary infections show that IgG rises within 1-2 days after the onset of symptoms and induces IgM response after 20 days of infection. iScreen Dengue NS1 by GenWorks offers an immunochromatographic one-step rapid card solution for qualitative early acute Dengue detection with NS1 antigen and differential detection of Dengue IgG & IgM antibodies in human serum.

The IVD tests for Malaria and Dengue are ways to ensure that the prevention of vector-borne diseases is conducted in all settings including the rural and resource-scarce ones with results being available within minutes. These tests are extremely reliable, quick, and even convenient which is why testing becomes the first line of defence against these diseases. From the very first sign of illness and relevant symptoms, efforts should be made to conduct tests so that the patients can be offered necessary and remedial medical attention without loss of time. These tests can prevent any fatal consequences.

With the Rapid Card kits for Malaria and Dengue, GenWorks aims to make healthcare solutions affordable, accessible, and equitable. These kits are a step to ensure a growing awareness of the importance of timely and accurate diagnosis of diseases amongst the Indian population.

https://www.genworkshealth.com/

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

Business

Rajputana Stainless Limited Crosses Rs. 1,000 Crores Revenue Milestone; FY-26 PAT rises 25.01% Y-O-Y to Rs. 49.82 crore

FY26 Net Profit rises 25.01% Y-o0-Y to Rs. 49.82 crore; Revenue from Operations crosses Rs. 1,000crore mark Vadodara (Gujarat) [India], June 03: Rajputana Stainless Limited, a leading stainless steel manufacturer, announced its audited financial results for the quarter ended 31st March 2026, reporting stable operational performance. It reported net profit of Rs. 49.82 crore for […]

Read More
Business

V-Green and ChargeZone Announce Strategic Partnership to Build Dedicated EV Charging Infrastructure Across India

First co-branded EV charging network to support VinFast’s India expansion; 100 additional stations planned Vadodara (Gujarat) [India], June 03: V-Green, the EV charging infrastructure company within the Vingroup ecosystem, has entered into a strategic partnership with ChargeZone, India’s largest EV charging network, to jointly develop dedicated EV charging infrastructure and charging ecosystem support for VinFast […]

Read More
Business

greytHR Launches NAVOS: Agentic AI That Turns HR Intent Into Action

Bengaluru (Karnataka) [India], June 03: greytHR, India’s most trusted full-suite HRMS for hire-to-retire solutions, today announced the launch of NAVOS — an Agentic AI Assistant built directly into its HRMS platform. Serving over 34,000 organisations across 25+ countries, greytHR manages 3.2 million+ employees and processes over USD 23 billion in payroll annually across India, the Middle East, and Southeast […]

Read More